These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

657 related articles for article (PubMed ID: 32458378)

  • 1. Metabolism and Pharmacokinetic Drug-Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer Studies.
    Boettcher M; Gerisch M; Lobmeyer M; Besche N; Thomas D; Gerrits M; Lemmen J; Mueck W; Radtke M; Becker C
    Clin Pharmacokinet; 2020 Nov; 59(11):1407-1418. PubMed ID: 32458378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic and Pharmacokinetic Interaction Profile of Vericiguat: Results from Three Randomized Phase I Studies in Healthy Volunteers.
    Boettcher M; Loewen S; Gerrits M; Becker C
    Clin Pharmacokinet; 2021 Mar; 60(3):337-351. PubMed ID: 33030703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study.
    Pieske B; Maggioni AP; Lam CSP; Pieske-Kraigher E; Filippatos G; Butler J; Ponikowski P; Shah SJ; Solomon SD; Scalise AV; Mueller K; Roessig L; Gheorghiade M
    Eur Heart J; 2017 Apr; 38(15):1119-1127. PubMed ID: 28369340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial.
    Armstrong PW; Roessig L; Patel MJ; Anstrom KJ; Butler J; Voors AA; Lam CSP; Ponikowski P; Temple T; Pieske B; Ezekowitz J; Hernandez AF; Koglin J; O'Connor CM
    JACC Heart Fail; 2018 Feb; 6(2):96-104. PubMed ID: 29032136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, pharmacodynamic, and pharmacokinetic characterization of vericiguat: results from six phase I studies in healthy subjects.
    Boettcher M; Thomas D; Mueck W; Loewen S; Arens E; Yoshikawa K; Becker C
    Eur J Clin Pharmacol; 2021 Apr; 77(4):527-537. PubMed ID: 33125516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction: The SOCRATES-REDUCED Randomized Trial.
    Gheorghiade M; Greene SJ; Butler J; Filippatos G; Lam CS; Maggioni AP; Ponikowski P; Shah SJ; Solomon SD; Kraigher-Krainer E; Samano ET; Müller K; Roessig L; Pieske B;
    JAMA; 2015 Dec; 314(21):2251-62. PubMed ID: 26547357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vericiguat, a novel sGC stimulator: Mechanism of action, clinical, and translational science.
    Trujillo ME; Ayalasomayajula S; Blaustein RO; Gheyas F
    Clin Transl Sci; 2023 Dec; 16(12):2458-2466. PubMed ID: 37997225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Applied physiologically-based pharmacokinetic modeling to assess uridine diphosphate-glucuronosyltransferase-mediated drug-drug interactions for Vericiguat.
    Frechen S; Ince I; Dallmann A; Gerisch M; Jungmann NA; Becker C; Lobmeyer M; Trujillo ME; Xu S; Burghaus R; Meyer M
    CPT Pharmacometrics Syst Pharmacol; 2024 Jan; 13(1):79-92. PubMed ID: 37794724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and mass balance of vericiguat in rats and dogs and distribution in rats.
    Janssen W; Schwarz T; Bütehorn U; Steinke W; Sandmann S; Lang D; Kern A; Hucke F; Gerisch M
    Xenobiotica; 2022 May; 52(5):453-462. PubMed ID: 35616579
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study.
    Filippatos G; Maggioni AP; Lam CSP; Pieske-Kraigher E; Butler J; Spertus J; Ponikowski P; Shah SJ; Solomon SD; Scalise AV; Mueller K; Roessig L; Bamber L; Gheorghiade M; Pieske B
    Eur J Heart Fail; 2017 Jun; 19(6):782-791. PubMed ID: 28586537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vericiguat: A Novel Oral Soluble Guanylate Cyclase Stimulator for the Treatment of Heart Failure.
    Campbell N; Kalabalik-Hoganson J; Frey K
    Ann Pharmacother; 2022 May; 56(5):600-608. PubMed ID: 34431706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.
    Armstrong PW; Pieske B; Anstrom KJ; Ezekowitz J; Hernandez AF; Butler J; Lam CSP; Ponikowski P; Voors AA; Jia G; McNulty SE; Patel MJ; Roessig L; Koglin J; O'Connor CM;
    N Engl J Med; 2020 May; 382(20):1883-1893. PubMed ID: 32222134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vericiguat: First Approval.
    Markham A; Duggan S
    Drugs; 2021 Apr; 81(6):721-726. PubMed ID: 33770393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of vericiguat: The first soluble guanylate cyclase (sGC) stimulator launched for heart failure with reduced ejection fraction (HFrEF).
    Xia J; Hui N; Tian L; Liang C; Zhang J; Liu J; Wang J; Ren X; Xie X; Wang K
    Biomed Pharmacother; 2022 May; 149():112894. PubMed ID: 35367763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonclinical Cardiovascular Assessment of the Soluble Guanylate Cyclase Stimulator Vericiguat.
    Himmel H; Lagrutta A; Vömel M; Amin RP; Imredy JP; Johnson T; Vinzing M; Prescott J; Blaustein RO
    J Pharmacol Exp Ther; 2023 Jul; 386(1):26-34. PubMed ID: 37068911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vericiguat: The First Soluble Guanylate Cyclase Stimulator for Reduction of Cardiovascular Death and Heart Failure Hospitalization in Patients With Heart Failure Reduced Ejection Fraction.
    Tran BA; Serag-Bolos ES; Fernandez J; Miranda AC
    J Pharm Pract; 2023 Aug; 36(4):905-914. PubMed ID: 35356844
    [No Abstract]   [Full Text] [Related]  

  • 17. Vericiguat for the treatment of heart failure: mechanism of action and pharmacological properties compared with other emerging therapeutic options.
    Hulot JS; Trochu JN; Donal E; Galinier M; Logeart D; De Groote P; Juillière Y
    Expert Opin Pharmacother; 2021 Oct; 22(14):1847-1855. PubMed ID: 34074190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure.
    Follmann M; Ackerstaff J; Redlich G; Wunder F; Lang D; Kern A; Fey P; Griebenow N; Kroh W; Becker-Pelster EM; Kretschmer A; Geiss V; Li V; Straub A; Mittendorf J; Jautelat R; Schirok H; Schlemmer KH; Lustig K; Gerisch M; Knorr A; Tinel H; Mondritzki T; Trübel H; Sandner P; Stasch JP
    J Med Chem; 2017 Jun; 60(12):5146-5161. PubMed ID: 28557445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of vericiguat in management of patients with heart failure with reduced ejection fraction after worsening episode.
    Olivella A; Almenar-Bonet L; Moliner P; Coloma E; Martínez-Rubio A; Paz Bermejo M; Boixeda R; Cediel G; Méndez Fernández AB; Facila Rubio L
    ESC Heart Fail; 2024 Apr; 11(2):628-636. PubMed ID: 38158630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population Pharmacokinetics and Pharmacodynamics of Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction.
    Ruehs H; Klein D; Frei M; Grevel J; Austin R; Becker C; Roessig L; Pieske B; Garmann D; Meyer M
    Clin Pharmacokinet; 2021 Nov; 60(11):1407-1421. PubMed ID: 34086190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.